Literature DB >> 17994212

[Topical therapy of balanitis xerotica obliterans in childhood. Long-term clinical results and an overview].

A-K Ebert1, T Vogt, W H Rösch.   

Abstract

Balanitis xerotica obliterans (BXO) is a chronic and progressive dermatitis of unknown aetiology and incidence. Its management in childhood is controversial. Although in most cases only the prepuce is affected, meatal and urethral involvement may lead to major surgical reconstruction. Therefore complete surgical excision of the affected skin is considered to be mandatory. In case of involvement, incidental histological evidence or a relapse, or when complete removal of the affected skin is not possible, a topical therapy should be implemented. In a retrospective analysis of our study population (13 children) with BXO, relapse rate was lower after topical therapy with tacrolimus (Protopic), a highly selective immune modulator, than after the standard anti-inflammatory therapy with betamethasone. The use of tacrolimus ointment is a safe therapy with no severe side effects. Due to the fact that there are no predictive factors for progression or relapse of BXO, we consider a topical anti-inflammatory therapy is always indicated after any type of surgery for BXO. Follow-up monitoring should be close, so that any relapse can be detected and treated as early as possible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994212     DOI: 10.1007/s00120-007-1577-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  19 in total

1.  Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus: evidence for loss of androgen receptors in lesional epidermis.

Authors:  M M Clifton; I B Garner; S Kohler; B R Smoller
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

Review 2.  Balanitis xerotica obliterans--a review.

Authors:  S Das; H S Tunuguntla
Journal:  World J Urol       Date:  2000-12       Impact factor: 4.226

Review 3.  The treatment of balanitis xerotica obliterans.

Authors:  I Depasquale; A J Park; A Bracka
Journal:  BJU Int       Date:  2000-09       Impact factor: 5.588

Review 4.  Lichen sclerosus in children.

Authors:  Janet McLelland
Journal:  J Obstet Gynaecol       Date:  2004-10       Impact factor: 1.246

Review 5.  Lichen sclerosus.

Authors:  J J Meffert; B M Davis; R E Grimwood
Journal:  J Am Acad Dermatol       Date:  1995-03       Impact factor: 11.527

6.  Lymphohistiocytic and granulomatous phlebitis in penile lichen sclerosus.

Authors:  P Cabaleiro; R M Drut; R Drut
Journal:  Am J Dermatopathol       Date:  2000-08       Impact factor: 1.533

7.  Lichen sclerosus et atrophicus in children with phimosis and hypospadias.

Authors:  G Mattioli; P Repetto; C Carlini; C Granata; C Gambini; V Jasonni
Journal:  Pediatr Surg Int       Date:  2002-05       Impact factor: 1.827

8.  Successful treatment of anogenital lichen sclerosus with topical tacrolimus.

Authors:  Markus Böhm; Uta Frieling; Thomas A Luger; Gisela Bonsmann
Journal:  Arch Dermatol       Date:  2003-07

9.  The histologic spectrum of prepuces from patients with phimosis.

Authors:  O J Clemmensen; J Krogh; M Petri
Journal:  Am J Dermatopathol       Date:  1988-04       Impact factor: 1.533

Review 10.  Assigning new roles to topical tacrolimus.

Authors:  Eustathios Rallis; Chrysovalantis Korfitis; Stamatis Gregoriou; Dimitris Rigopoulos
Journal:  Expert Opin Investig Drugs       Date:  2007-08       Impact factor: 6.206

View more
  2 in total

1.  Case of a congenital urethral duplication being unmasked following circumcision for balanitis xerotica obliterans.

Authors:  Matthew Boyd; Mark Woodward; Anthony Lambert
Journal:  Ann R Coll Surg Engl       Date:  2010-06-07       Impact factor: 1.891

2.  Management of boys with abnormal appearance of meatus at circumcision for balanitis xerotica obliterans.

Authors:  C Holbrook; T Tsang
Journal:  Ann R Coll Surg Engl       Date:  2011-09       Impact factor: 1.891

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.